Singular Genomics Systems, Inc.

NasdaqCM:OMIC Stock Report

Market Cap: US$50.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Singular Genomics Systems (OMIC) Stock Overview

A life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. More details

OMIC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 95.18% per year

Risk Analysis

Does not have meaningful revenue ($3M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($51M)


OMIC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Singular Genomics Systems, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Singular Genomics Systems
Historical stock prices
Current Share PriceUS$20.01
52 Week HighUS$23.41
52 Week LowUS$5.34
Beta1.84
1 Month Change0.81%
3 Month Change-6.58%
1 Year Change21.27%
3 Year Change-91.92%
5 Year Changen/a
Change since IPO-97.41%

Recent News & Updates

Recent updates

Singular Genomics cut to Neutral at UBS on delays for sequencer shipments

Aug 17

Singular Genomics Systems GAAP EPS of -$0.34

Aug 09

Shareholder Returns

OMICUS Life SciencesUS Market
7D0.3%2.2%2.1%
1Y21.3%-15.6%14.3%

Return vs Industry: OMIC exceeded the US Life Sciences industry which returned -14.6% over the past year.

Return vs Market: OMIC matched the US Market which returned 20.8% over the past year.

Price Volatility

Is OMIC's price volatile compared to industry and market?
OMIC volatility
OMIC Average Weekly Movement3.7%
Life Sciences Industry Average Movement10.2%
Market Average Movement7.4%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.9%

Stable Share Price: OMIC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: OMIC's weekly volatility has decreased from 22% to 4% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016255Drew Spaventawww.singulargenomics.com

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

Singular Genomics Systems, Inc. Fundamentals Summary

How do Singular Genomics Systems's earnings and revenue compare to its market cap?
OMIC fundamental statistics
Market capUS$50.70m
Earnings (TTM)-US$86.32m
Revenue (TTM)US$2.67m
19.0x
P/S Ratio
-0.6x
P/E Ratio

Is OMIC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OMIC income statement (TTM)
RevenueUS$2.67m
Cost of RevenueUS$4.02m
Gross Profit-US$1.35m
Other ExpensesUS$84.97m
Earnings-US$86.32m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-34.07
Gross Margin-50.77%
Net Profit Margin-3,236.67%
Debt/Equity Ratio8.4%

How did OMIC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 01:23
End of Day Share Price 2025/02/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Singular Genomics Systems, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael RyskinBofA Global Research
null nullEquisights
Matthew SykesGoldman Sachs